seeing is believing
The FIRST BIOLOGIC for adults with moderate-to-severe
ATOPIC DERMATITIS who are candidates for systemic therapy3
NICE, The National Institute of Health and Care Excellence; SMC, Scottish Medicines Consortium.
1. Blauvelt A, et al. Lancet. 2017;389(10086):2287-2303. 2. Paller A, et al. Poster presented at the 77th annual meeting of the American Academy of Dermatology; 2019; March 1–5: Washington, DC, USA. Poster 10051. 3. DUPIXENT Summary of Product Characteristics. 4. Simpson EL, et al. New Engl J Med. 2016;375(24):2335–2348. 5. De Bruin-Weller, et al. Br J Dermatol. 2017;178:1083–1101. 6. Sanofi Data on File. SAGB.DUP.17.09.1126. September 2017. 7. © NICE  Dupilumab for treating moderate to severe atopic dermatitis. Available from: https://www.nice.org.uk/guidance/TA534/chapter/1-Recommendations. All rights reserved. Subject to notice of rights. NICE guidance is prepared for the National Health Service in England. All NICE guidance is subject to regular review and may be updated or withdrawn. NICE accepts no responsibility for the use of its content in this product/publication. 8. Scottish Medicines Consortium. Dupilumab (Dupixent). Available from: https://www.scottishmedicines.org.uk/medicines-advice/dupilumab-dupixent-fullsubmission-smc2011/.